Complexin-4 Inhibitors
Complexin-4 inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of Complexin-4, a protein that plays a critical role in the regulation of synaptic vesicle exocytosis within the nervous system. Complexin-4 is part of the complexin family of proteins, which are known for their ability to modulate the SNARE (Soluble NSF Attachment Protein Receptor) complex, a crucial component in the process of neurotransmitter release at synaptic junctions. By binding to the SNARE complex, Complexin-4 acts as a regulatory clamp that can either promote or inhibit the fusion of synaptic vesicles with the presynaptic membrane, thereby influencing the timing and efficiency of neurotransmitter release. Inhibitors of Complexin-4 are molecules that interfere with this regulatory function, potentially altering the dynamics of synaptic transmission by disrupting the normal interaction between Complexin-4 and the SNARE complex.
The development of Complexin-4 inhibitors involves an in-depth understanding of the protein's structure, particularly its interaction domains that bind to the SNARE complex. These inhibitors are typically designed to target specific regions of Complexin-4, such as its alpha-helical domain, which is essential for its binding affinity to the SNARE proteins. By binding to these critical sites, Complexin-4 inhibitors can prevent the protein from exerting its modulatory effects on vesicle fusion, thereby affecting the release of neurotransmitters at synapses. This disruption can lead to changes in synaptic signaling, potentially altering the balance of excitatory and inhibitory neurotransmission in neural circuits. The specificity of these inhibitors is crucial, as Complexin-4 shares structural similarities with other complexin family members, necessitating the development of compounds that can selectively inhibit Complexin-4 without affecting the function of other complexins. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and molecular dynamics simulations are employed to elucidate the binding interactions and optimize the affinity and selectivity of these inhibitors. Additionally, high-throughput screening and structure-activity relationship (SAR) studies are used to identify and refine compounds that effectively target Complexin-4, ensuring that the inhibitors are both potent and precise in modulating synaptic vesicle exocytosis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase. By inhibiting this pump, it causes an increase in vesicular pH. Elevated vesicular pH can indirectly affect neurotransmitter uptake and storage, potentially enhancing the functional requirement for CPLX4 in neurotransmitter release. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing the intracellular concentration of cAMP. Elevated cAMP can lead to activation of PKA, which may phosphorylate proteins involved in neurotransmitter release, potentially enhancing the functional activity of CPLX4 in the synaptic vesicle cycle. | ||||||
Veratridine | 71-62-5 | sc-201075B sc-201075 sc-201075C sc-201075A | 5 mg 10 mg 25 mg 50 mg | $82.00 $104.00 $201.00 $379.00 | 3 | |
Veratridine is an alkaloid that modulates voltage-gated sodium channels. By preventing channel inactivation, veratridine prolongs action potentials, which could increase neurotransmitter release and indirectly increase the demand for CPLX4's regulatory role in exocytosis. | ||||||
4-Aminopyridine | 504-24-5 | sc-202421 sc-202421B sc-202421A | 25 g 1 kg 100 g | $38.00 $1155.00 $122.00 | 3 | |
4-Aminopyridine is a potassium channel blocker. By blocking voltage-gated potassium channels, it prolongs neuronal action potentials, potentially increasing the requirement for CPLX4's role in neurotransmitter release. | ||||||
Tetraethylammonium chloride | 56-34-8 | sc-202834 | 25 g | $45.00 | 2 | |
Tetraethylammonium chloride (TEA) is another potassium channel blocker. Similar to 4-aminopyridine, it can enhance neurotransmitter release by prolonging action potentials, which could necessitate an increased function of CPLX4 in synaptic vesicle exocytosis. | ||||||
Methyllycaconitine citrate | 112825-05-5 | sc-253043 sc-253043A | 5 mg 25 mg | $119.00 $406.00 | 2 | |
Methyllycaconitine is an antagonist of α7-nicotinic acetylcholine receptors. This compound can modulate synaptic transmission, potentially impacting the regulatory role of CPLX4 in neurotransmitter release. | ||||||
ω-Agatoxin IVA | 145017-83-0 | sc-302015 | 100 µg | $463.00 | ||
ω-Agatoxin IVA is a P-type calcium channel blocker. Inhibition of these channels alters synaptic transmission and could require increased functional activity of CPLX4 for the fine-tuning of neurotransmitter release. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
Ryanodine locks ryanodine receptors in an open state at nanomolar concentrations, leading to depletion of calcium stores from the sarcoplasmic/endoplasmic reticulum. Altered calcium dynamics can influence synaptic transmission and thus the functional activity of CPLX4. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine is another L-type calcium channel blocker. It can affect neurotransmitter release by modulating calcium influx, thereby potentially influencing the role of CPLX4 in synaptic vesicle dynamics. | ||||||